Showing 2626 results
- https://www.novartis.com/news/novartis-coronavirus-update-supply-chain-response-measures-efpia-rd-call
- https://www.novartis.com/news/expanding-car-t-manufacturing-australia
Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world. - https://www.novartis.com/news/media-releases/new-peer-reviewed-research-shows-no-increased-risk-serious-covid-19-infections-kesimpta-ofatumumab-treated-adults-multiple-sclerosisThe study published in ‘Neurology and Therapy’ also shows the fatal outcomes and hospitalization rates due to COVID-19 in those treated with Kesimpta were in line with the rates in the general MS…
- https://www.novartis.com/news/media-releases/sandoz-targets-growth-opportunities-respiratory-and-complex-generics-through-acquisition-respiratory-device-company-coalesceSandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics Respiratory diseases are leading…
- https://www.novartis.com/news/media-releases/novartis-data-again-demonstrate-age-appropriate-development-when-zolgensma-used-presymptomatically-and-post-hoc-data-reveal-sma-type-1-patients-could-speak-swallow-and-maintain-airway-protectionChildren with three copies of SMN2 treated presymptomatically achieved age-appropriate milestones, including standing and walking; required no ventilatory or feeding tube support; and had no serious…
- https://www.novartis.com/news/media-releases/novartis-signs-initial-agreement-carisma-therapeutics-manufacturing-her-2-targeted-car-m-cell-therapyInitial agreement covers reservation of state-of-the-art cell and gene facility in Morris Plains, U.S.HER 2 targeted CAR-M cell therapy is tested in initial trials for the treatment of solid…
- https://www.novartis.com/news/media-releases/nejm-publication-novartis-kisqali-data-shows-longest-median-overall-survival-ever-reported-hrher2-advanced-breast-cancerMONALEESA-2 results show a statistically significant more than one-year increase in survival for women with HR+/HER2- postmenopausal aBC when using Kisqali plus letrozole compared to letrozole alone…
- https://www.novartis.com/news/media-releases/novartis-voyager-therapeutics-reach-license-option-agreement-next-generation-gene-therapy-vectors-neurological-diseasesNovartis gains target-specific access to next-generation AAV capsids that could be used for three diseases of the central nervous system, with options for two additional targets Agreement builds on…
- https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-5Shareholders approve 25th consecutive dividend increase to CHF 3.10 (+3.3%) per share for 2021; representing a 3.9% yield1 and approximately 57% payout of free cash flowShareholders confirm Dr. Joerg…
- https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-ordinaireLes actionnaires approuvent la 25e augmentation consécutive du dividende qui passe à CHF 3.10 (+3,3%) par action pour 2021; représentant un rendement de 3.9%1 et une distribution du free cash-flow d’…